natgillin/translations-raw huggingface dataset:
Some of the side effects connected with Firazyr are similar to the symptoms of your disease.
Nekateri neželeni učinki, povezani z uporabo zdravila Firazyr, so podobni simptomom vaše bolezni.
This area should be at least 5 cm (2 inches) away from any scars.
To mesto mora biti vsaj 5 cm oddaljeno od kakršnih koli brazgotin.
Firazyr should be used during pregnancy only, if the potential benefit justifies the potential risk for the foetus, (e.g for treatment of potentially life threatening laryngeal attacks).
Zdravilo Firazyr se sme uporabljati med nosečnostjo samo, če možna korist odtehta možno tveganje za plod (npr. pri zdravljenju morebitnih življenjsko ogrožajočih laringealnih napadov).
Each Firazyr syringe is intended for single use only.
Vsaka brizga zdravila Firazyr je namenjena le enkratni uporabi.
In the first 15 Firazyr treated attacks (1,114 doses for 1,030 attacks), the median times to onset of symptom relief were similar across attacks (2.0 to 2.5 hours).
Pri prvih 15 napadih, ki so jih zdravili z zdravilom Firazyr (1114 odmerkov za 1030 napadov), je bila mediana časa do pojava olajšanja simptomov podobna pri vseh napadih (od 2,0 do 2,5 ure).
A hypodermic needle (25 G; 16 mm) is included in the pack.
Igla za subkutano aplikacijo (25 G; 16 mm) je priložena pakiranju.
• Hold the syringe in one hand between two fingers with your thumb at the bottom of the plunger.
• Brizgo držite med dvema prstoma ene roke, pri čemer je palec na spodnjem delu bata.
The results were similar to patients with non-laryngeal attacks of HAE with respect to time to onset of symptom relief.
Rezultati so bili podobni kot pri bolnikih z nelaringealnimi napadi HAE glede na čas do pojava lajšanja simptomov.
The pharmacokinetic profile of icatibant in patients with HAE is similar to that in healthy volunteers.
Farmakokinetični profil ikatibanta pri bolnikih s HAE je podoben kot pri zdravih prostovoljcih.
These reactions were erythema, swelling, burning and warm sensation.
Te reakcije so bile eritem, otekanje, pekoč občutek in občutek toplote.
Do not pull up on the plunger.
Ne vlecite za bat.
Icatibant had no effect on the fertility of male mice and rats (see section 5.3).
Ikatibant ni imel nobenega učinka na plodnost mišjih in podganjih samcev (glejte poglavje 5.3).
HAE (an autosomal dominant disease) is caused by an absence or dysfunction of C1-esteraseinhibitor.
Hereditarni angioedem (HAE) (avtosomna dominantna bolezen) se pojavi zaradi odsotnosti ali disfunkcije zaviralca C1-esteraze.
* Injection site bruising, Injection site hematoma, Injection site burning, Injection site erythema, Injection site hypoesthesia, Injection site irritation, Injection site numbness, Injection site edema, Injection site pain, Injection site pressure sensation, Injection site pruritus, Injection site swelling, Injection site urticaria, and Injection site warmth.
* Podplutba na mestu injiciranja, hematom na mestu injiciranja, pekoč občutek na mestu injiciranja, eritem na mestu injiciranja, hipoestezija na mestu injiciranja, draženje na mestu injiciranja, otopelost na mestu injiciranja, edem na mestu injiciranja, bolečina na mestu injiciranja, občutek pritiska na mestu injiciranja, pruritus na mestu injiciranja, otekanje na mestu injiciranja, urtikarija na mestu injiciranja in občutek toplote na mestu injiciranja.
- If your symptoms get worse or do not improve, you must seek immediate medical help.
- Če se vaši simptomi poslabšajo, ali če se ne izboljšajo, se takoj posvetujte z zdravnikom.
What you need to know before you use Firazyr Do not use Firazyr
Kaj morate vedeti, preden boste uporabili zdravilo Firazyr Ne uporabljajte zdravila Firazyr
In the majority of cases a single injection of Firazyr is sufficient to treat an attack.
V večini primerov zadošča za zdravljenje napada ena injekcija zdravila Firazyr.
• Hold syringe between 45-90 degrees angle to skin with needle facing the skin.
• Brizgo držite pod kotom med 45 in 90 stopinjami glede na kožo, igla pa naj bo obrnjena proti koži.
Contents of the pack and other information What Firazyr contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Firazyr
Icatibant did not elicit any cardiac conduction change in vitro (hERG channel) or in vivo in normal dogs or in various dog models (ventricular pacing, physical exertion and coronary ligation) where no associated hemodynamic changes were observed.
Ikatibant ni izzval sprememb srčne prevodnosti in vitro (kanal hERG) ali in vivo pri normalnih psih ali pri različnih modelih psov (prekatno spodbujanje, telesni napor in koronarna ligacija), kjer niso bile opažene nobene s tem povezane hemodinamske spremembe.
Following subcutaneous administration, the absolute bioavailability of icatibant is 97%.
Absorpcija Po subkutani aplikaciji je absolutna biološka uporabnost ikatibanta 97 %.
If you have never received Firazyr previously, your first dose of Firazyr will always be injected by your doctor or nurse.
Če niste še nikoli prejeli zdravila Firazyr, vam bo prvi odmerek injiciral vaš zdravnik ali medicinska sestra.
Not known (frequency cannot be estimated from the available data) : Hives (urticaria)
Neznanao (pogostosti ni mogoče oceniti iz razpoložljivih podatkov):
Icatibant is excreted in the milk of lactating rats at concentrations similar to those in maternal blood.
Ikatibant se pri podganah izloča v mleko v koncentracijah, ki so podobne koncentracijam v krvi samic.
Patients with laryngeal attacks should be managed in an appropriate medical institution after injection until the physician considers discharge to be safe.
Bolnike z laringealnimi napadi je treba po injiciranju obravnavati v ustrezni zdravstveni ustanovi, dokler zdravnik ne presodi, da je odpust varen.
In a study of 39 healthy adult men and women treated with 30 mg every 6 hours for 3 doses every 3 days for a total of 9 doses, there were no clinically significant changes from baseline in basal and GnRH-stimulated concentration of reproductive hormones in either females or males.
V študiji pri 39 zdravih odraslih moških in ženskah, ki so jih zdravili s 30 mg vsakih 6 ur v 3 odmerkih vsake 3 dni, kar je pomenilo skupno 9 odmerkov, niso ugotovili nobenih klinično pomembnih sprememb od izhodiščnih vrednosti pri bazalni in z GnRH stimulirani koncentraciji reproduktivnih hormonov pri nobenem od spolov.
Icatibant is extensively metabolized by proteolytic enzymes to inactive metabolites that are primarily excreted in the urine.
Biotransformacija Ikatibant obsežno presnavljajo proteolitični encimi v neaktivne presnovke, ki se primarno izločajo z urinom.
Following a single subcutaneous administration (0.4 mg/kg up to a maximum of 30 mg), the time to maximum concentration is approximately 30 minutes and the terminal half-life is about 2 hours.
Po subkutanem injiciranju posameznega odmerka (0,4 mg/kg do največ 30 mg) je čas do doseganja največje koncentracije približno 30 minut, končni razpolovni čas pa je približno 2 uri.
The treatment effect of icatibant was confirmed by secondary efficacy endpoints.
Učinek zdravljenja z ikatibantom so potrdili sekundarni pokazatelji učinkovitosti.
• Grip the syringe firmly.
• Trdno primite brizgo.
Firazyr has minor influence on the ability to drive and use machines.
Zdravilo Firazyr ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Difference between treatments (95% CI, p-value)
Razlika med zdravljenji (95 %
Median time to onset of symptom relief: all symptoms (hours): Abdominal pain Skin swelling Skin pain
Mediana časa do nastopa olajšanja simptomov: vsi simptomi (v urah): bolečina v trebuhu oteklina na koži bolečine v koži
Icatibant is a potent antagonist of bradykinin and therefore, at high dose levels, treatment can have effects on the uterine implantation process and subsequent uterine stability in early pregnancy.
Ikatibant je močan antagonist bradikinina, zato lahko zdravljenje z visokimi odmerki vpliva na proces ugnezdenja v maternico in nadaljnjo stabilnost v maternici v zgodnji nosečnosti.
What Firazyr is and what it is used for
Kaj je zdravilo Firazyr in za kaj ga uporabljamo
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor before starting to use Firazyr.
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se pred začetkom zdravljenja z zdravilom Firazyr posvetujte s svojim zdravnikom.
2b) Preparing the syringe and needle for injection: All patients (adults, adolescents and children)
Priprava brizge in igle za injiciranje: Vsi bolniki (odrasli, mladostniki in otroci)
The appropriate dose to be administered is based on body weight (see section 4.2).
Ustrezen odmerek temelji na telesni masi (glejte poglavje 4.2).
• Discard the syringe, needle and needle cap into the sharp container for throwing away waste that might hurt others if not handled properly.
• Brizgo, iglo in pokrovček za iglo odvrzite v vsebnik za odstranjevanje ostrih predmetov, ki lahko povzročijo poškodbo, če se ne uporabljajo pravilno.
In a 2 year study to evaluate the carcinogenic potential of icatibant in rats, daily doses giving exposure levels up to approximately 2-fold that achieved after a therapeutic dose in humans had no effect on the incidence or morphology of tumours.
V 2-letni študiji za ugotovitev karcinogenega potenciala ikatibanta pri podganah dnevni odmerki z do približno 2-kratno stopnjo izpostavljenosti v primerjavi s stopnjo, doseženo pri terapevtskem odmerku pri ljudeh, niso imeli vpliva na pojavnost ali morfologijo tumorjev.
Although there is evidence to support a beneficial effect of B2 receptor blockade immediately following a stroke, there is a theoretical possibility that icatibant may attenuate the positive late phase neuroprotective effects of bradykinin.
Kljub dokazanemu ugodnemu učinku blokade receptorja B2 neposredno po možganski kapi je teoretično mogoče, da ikatibant oslabi pozitivne zaščitne učinke bradikinina na živčne celice v pozni fazi.
There were no significant effects of icatibant on the concentration of luteal phase progesterone and luteal function, or on menstrual cycle length in females and there were no significant effects of icatibant on sperm count, motility and morphology in males.
Opazili niso nobenega pomembnega učinka ikatibanta na koncentracijo progesterona v luteinski fazi in luteinsko delovanje ali na dolžino menstruacijskega cikla pri ženskah, prav tako pa ni bilo nobenih pomembnih učinkov ikatibanta na število, gibljivost in morfologijo semenčic pri moških.
Adults The recommended dose for adults is a single subcutaneous injection of Firazyr 30 mg.
Priporočeni odmerek pri odraslih je eno subkutano injiciranje 30 mg zdravila Firazyr.
It is important that Firazyr is injected subcutaneously (under the skin) as soon as you notice an attack of angioedema.
Pomembno je, da si zdravilo subkutano (podkožno) injicirate, takoj ko opazite napad angioedema.
Shire Pharmaceuticals Ireland Limited
DRUGI PODATKI Shire Pharmaceuticals Ireland Limited
In clinical studies used for registration, a total of 999 HAE attacks have been treated with 30 mg Firazyr administered subcutaneously by a healthcare professional.
V kliničnih študijah za registracijo zdravila so skupno 999 napadov HAE zdravili s 30 mg zdravila Firazyr, ki so ga subkutano dajali zdravstveni delavci.
In healthy young subjects, icatibant administered in doses of 0.8 mg/kg over 4 hours; 1.5 mg/kg/day or 0.15 mg/kg/day for 3 days, development of bradykinin-induced hypotension, vasodilatation and reflex tachycardia was prevented.
Pri zdravih mladih osebah so ikatibant dajali v odmerkih 0,8 mg/kg v 4 urah; 1,5 mg/kg/dan ali 0,15 mg/kg/dan 3 dni; pojav hipotenzije, vazodilatacije in refleksne tahikardije zaradi bradikinina je bil preprečen.
(Common, ≥1/100 to <1/10)
(pogosti, ≥ 1/100 do < 1/10)
Icatibant is mainly eliminated by metabolism with less than 10% of the dose eliminated in the urine as unchanged drug.
Ikatibant se izloča pretežno presnovljen, manj kot 10 % odmerka pa se izloči z urinom v nespremenjeni obliki.
Phase III clinical studies (FAST-1 and FAST-2) were randomized, double-blind, controlled trials and had identical designs except for the comparator (one with oral tranexamic acid as the comparator and one placebo controlled).
Klinične študije 3. faze (FAST-1 in FAST-2) so bila randomizirana, dvojno slepa, nadzorovana preskušanja in so imele enake načrte, razen za primerjalno zdravilo (v eni je bilo zdravilo primerjano s peroralno traneksaminsko kislino in v drugi s placebom).
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Druga zdravila in zdravilo Firazyr Obvestite svojega zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Table 1: Dosage regimen for paediatric patients Body Weight
Preglednica 1: Režim odmerjanja pri pediatričnih bolnikih
Your healthcare provider will teach you and your caregiver how to safely inject Firazyr by following the instructions in the Package Leaflet.
Zdravstveno osebje bo vas in vašega negovalca poučilo, kako varno injicirati zdravilo Firazyr, pri čemer je treba upoštevati navodilo za uporabo.
In the pivotal juvenile toxicity study in which sexually immature rats were treated daily with 3 mg/kg/day for 7 weeks, atrophy of testes and epididymides were observed; the observed microscopic findings were partially reversible.
V ključni študiji toksičnosti za razvoj mladičev, v kateri so spolno nezrele podgane zdravili s 3 mg/kg na dan 7 tednov, so opazili atrofijo testisov in epididimisa; opažene mikroskopske ugotovitve so bile delno reverzibilne.
Where the required dose is less than 30 mg (3 ml), the following equipment is required to extract and administer the appropriate dose:
Kadar je potreben odmerek manjši od 30 mg (3 ml), je za odmerjanje in dajanje ustreznega odmerka potrebna naslednja oprema:
ACE inhibitors are contraindicated in HAE patients due to possible enhancement of bradykinin levels.
Zaviralci ACE so kontraindicirani pri bolnikih s hereditarnim angioedemom zaradi možnega povišanja ravni bradikinina.
Firazyr is intended for subcutaneous injection (under the skin).
Zdravilo Firazyr je namenjeno za subkutano injekcijo (pod kožo).
Injection site reactions*
reakcije na mestu injiciranja*
Based on modelling for weight banded dosing, the predicted exposure to icatibant in the paediatric HAE population (see section 4.2) is lower than the observed exposure in studies conducted with adult HAE patients.
Na podlagi modeliranja za odmerjanje glede na telesno maso je predvidena izpostavljenost ikatibantu pri pediatrični populaciji z napadi HAE (glejte poglavje 4.2) nižja od opažene izpostavljenosti v študijah, opravljenih pri odraslih bolnikih z napadi HAE.
Controlled Clinical Study of FIRAZYR vs Tranexamic acid or Placebo: Efficacy Results FAST-2
Kontrolirana klinična študija zdravila FIRAZYR v primerjavi s traneksamično kislino/placebom: rezultati učinkovitosti
• Slowly push the plunger of the syringe with a steady hand until all the fluid is injected into the skin and no liquid remains in the syringe.
• Z mirno roko počasi potiskajte bat brizge, dokler se pod kožo ne injicira celotna tekočina in v brizgi ni več tekočine.
For adult patients, up to 2 additional injections may be given within 24 hours.
Pri odraslih bolnikih se lahko v roku 24 ur dasta 2 dodatni injekciji.
Firazyr solution for injection should be injected slowly due to the volume to be administered.
Raztopino za injiciranje Firazyr je treba injicirati počasi zaradi prostornine, ki jo je treba injicirati.
The pharmacokinetics of icatibant has been characterized by studies using both intravenous and subcutaneous administration to healthy volunteers and patients.
Farmakokinetične lastnosti ikatibanta so bile preučene v študijah, ki so vključevale intravensko in subkutano dajanje ikatibanta zdravim prostovoljcem in bolnikom.
Overall the median time to onset of symptom relief was 1.0 hour (95% confidence interval, 1.0-1.1 hours).
Skupno je bila mediana časa do nastopa izboljšanja simptomov 1,0 ure (95-odstotni interval zaupanja; 1,0-1,1 ure).
Preferred Term
Priporočeni izraz
HAE attacks are accompanied by an increased release of bradykinin, which is the key mediator in the development of the clinical symptoms.
Napade HAE spremlja povečano sproščanje bradikinina, ki je ključni posrednik pri pojavu kliničnih simptomov.
3) Attach the graduated syringe to the other end of the connector ensuring that both connections fit securely.
3) Pritrdite brizgo z oznakami prostornine na drugi konec vmesnika in poskrbite, da bo vse trdno pritrjeno.
Pharmacotherapeutic group: Other haematological agents, drugs used to treat hereditary angioedema;
Farmakoterapevtska skupina: druga krvna zdravila, zdravila za zdravljenje hereditarnega angioedema,
Change from baseline to 12 hours
Sprememba izhodiščne vrednosti na 12 ur
In both rats and dogs, repeated use of icatibant resulted in effects on reproductive organs.
Pri podganah in psih je ponavljajoča se uporaba ikatibanta povzročila učinke na spolne organe.
• Choose the injection site.
• Izberite mesto injiciranja.
Do not drive or use machines if you feel tired or dizzy as a result of your HAE attack or after using Firazyr.
Vpliv na sposobnost upravljanja vozil in strojev Ne vozite in ne upravljajte s stroji, če ste utrujeni ali omotični zaradi napada HAE ali po uporabi zdravila Firazyr.
Firazyr blocks the activity of bradykinin and therefore ends the further progression of the symptoms.
Zdravilo Firazyr zavira aktivnost bradikinina ter tako ustavi nadaljnje napredovanje simptomov napada HAE.
Overall, the median time to minimal symptoms (earliest time post treatment when all symptoms were either mild or absent) was 1.1 hours (95% confidence interval, 1.0-2.0 hours).
Skupno je mediana časa do minimalnih simptomov (najzgodnejši čas po odmerjanju zdravila, ko so bili vsi simptomi blagi, ali pa jih ni bilo) bila 1,1 ure (95-odstotni interval zaupanja; 1,0-2,0 ur).
These uterine effects also manifest in late stage pregnancy where icatibant exhibits a tocolytic effect resulting in delayed parturition in the rat, with increased fetal distress and perinatal death at high doses (10 mg/kg/day).
Ti učinki na maternico se kažejo tudi v poznem stadiju nosečnosti, ko ikatibant izkazuje tokolitičen učinek, kar se kaže v zakasneli kotitvi pri podganah, s povečanjem fetalnega distresa in perinatalne smrti pri visokih odmerkih (10 mg/kg/dan).
For adults, up to 2 additional injections may be given within 24 hours.
Pri odraslih se lahko v roku 24 ur dasta 2 dodatni injekciji.
Across repeated treatment in adults in the controlled phase III trials, transient positivity to antiicatibant antibodies was observed in rare cases.
V nadzorovanih preskušanjih 3. faze s ponavljajočimi se zdravljenji pri odraslih so v redkih primerih opazili prehodno pozitivnost za protitelesa proti ikatibantu.
Elderly people have been shown to have increased systemic exposure to icatibant.
Pri starejših bolnikih je bila dokazana večja sistemska izpostavljenost ikatibantu.
In these studies, patients on icatibant had a faster median time to onset of symptom relief (2.0, 2.5 and 2.0 hours, respectively) compared to tranexamic acid (12.0 hours) and placebo (4.6 and 19.8 hours).
V teh študijah so imeli bolniki, ki so prejemali ikatibant, krajšo mediano časa do nastopa olajšanja simptomov (2,0, 2,5 oziroma 2,0 ure) kot bolniki, ki so prejemali traneksamično kislino (12,0 ure) ali tisti, ki so prejemali placebo (4,6 oziroma 19,8 ure).
A dose of 3.2 mg/kg intravenously (approximately 8 times the therapeutic dose) caused transient erythema, itching, flushing or hypotension in healthy subjects.
Odmerek 3,2 mg/kg intravensko (približno 8-kratni terapevtski odmerek) je pri zdravih osebah povzročil prehodne eriteme, srbečico, vročinske oblive ali hipotenzijo.
One Firazyr-treated patient tested positive for anti-icatibant antibodies before and after treatment with Firazyr.
En bolnik, ki se je zdravil z zdravilom Firazyr, je bil pozitiven za protitelesa proti ikatibantu pred zdravljenjem z zdravilom Firazyr in po njem.
A subset of patients in this study experienced acute HAE attacks while receiving androgens, antifibrinolytic agents or Cl inhibitors.
Podskupina bolnikov v tej študiji je imela akutne napade HAE med jemanjem androgenov, antifibrinolitičnih učinkovin ali zaviralcev CI.
Icatibant was shown to be a competitive antagonist when the bradykinin challenge dose was increased 4-fold.
Ikatibant je izkazal lastnosti kompetitivnega antagonista, ko je bil provokacijski odmerek bradikinina povečan 4-kratno.
In HAE increased bradykinin concentrations are the key mediator in the development of the clinical symptoms.
Pri HAE so povečane koncentracije bradikinina ključni posrednik pri pojavu kliničnih simptomov.
Firazyr 30 mg SC has been administered by a healthcare professional to 129 healthy subjects and 236 patients with HAE.
Zdravstveni delavci so zdravilo Firazyr 30 mg subkutano dali 129 zdravim preskušancem in 236 bolnikom s HAE.
If there is air in the graduated syringe:
Če je v brizgi z oznakami za prostornino zrak:
These symptoms may occur as a result of an attack of HAE.
Ti simptomi se lahko pojavijo kot posledica napada hereditarnega angioedema.
How should Firazyr be administered?
Kako je treba dati zdravilo Firazyr?
Caution should therefore be observed in the administration of Firazyr to patients with acute ischemic heart disease or unstable angina pectoris (see section 5.3).
Zaradi tega je pri dajanju zdravila Firazyr bolnikom z akutno ishemično boleznijo srca ali nestabilno angino pektoris potrebna previdnost (glejte poglavje 5.3).
The majority of paediatric patients who were treated with subcutaneous icatibant experienced injection site reactions such as erythema, swelling, burning sensation, skin pain and itching/pruritus; these were found to be mild to moderate in severity and consistent with reactions that have been reported in adults.
Pri večini pediatričnih bolnikov, ki so prejeli ikatibant s subkutanim injiciranjem so se pojavile reakcije na mestu injiciranja, kot so eritem, otekanje, pekoč občutek, bolečine in srbenje/pruritus na koži; ugotovili so, da so te reakcije blage do zmerne in da so skladne z reakcijami, o katerih so poročali pri odraslih.
In the clinical trials, not more than 8 injections of Firazyr per month have been administered.
V kliničnih preskušanjih so v enem mesecu aplicirali največ 8 injekcij zdravila Firazyr.
Table 1: Dosage regimen for children and adolescents Body Weight
Preglednica 1: Režim odmerjanja za otroke in mladostnike
Change from baseline to 4 hours
Sprememba izhodiščne vrednosti na 4 ure
Pharmacokinetic drug interactions involving CYP450 are not expected (see section 5.2).
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Farmakokinetične interakcije, povezane s CYP450, niso pričakovane (glejte poglavje 5.2).
The efficacy population consisted of 22 patients who had been treated with icatibant (11 prepubertal and 11 pubertal/postpubertal) for HAE attack.
Populacija za ugotavljanje učinkovitosti je vključevala 22 bolnikov, pri katerih so napad HAE zdravili z ikatibantom (11 v predpuberteti in 11 v puberteti/postpuberteti).
• Release the skin fold and gently pull the needle out.
• Spustite kožno gubo in nežno izvlecite iglo.
Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.
Zdravilo Firazyr je indicirano za simptomatsko zdravljenje akutnih napadov hereditarnega (prirojenega) angioedema (HAE) pri odraslih, mladostnikih in otrocih, starih 2 leti ali več, s pomanjkanjem zaviralca C1-esteraze.
The required injection volume in ml should be drawn up in an empty 3 ml graduated syringe (see table below).
Potrebno prostornino odmerka za injiciranje v ml je treba izvleči v prazno brizgo z oznakami prostornine velikosti 3 ml (glejte spodnjo preglednico).
• Hold the fold of skin, bring the syringe to the skin and quickly insert the needle into the skin fold.
• Držite kožno gubo, brizgo približajte koži in iglo hitro vstavite v kožno gubo.
Firazyr is not known to interact with other medicines.
Ni znano, da bi zdravilo Firazyr medsebojno delovalo z drugimi zdravili.